Indication
In combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous NSCLC in adult.

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2187
Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
09 September 2019
SMC meeting date:
06 August 2019
Patient group submission deadline:
03 June 2019